Cargando…
Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study
PURPOSE: Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient’s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751154/ https://www.ncbi.nlm.nih.gov/pubmed/36510385 http://dx.doi.org/10.1177/15347354221140402 |
_version_ | 1784850409732440064 |
---|---|
author | Xiaozhe, Li Meilan, Chen Beihui, Huang Junru, Liu Jingli, Gu Lifen, Kuang Juan, Li |
author_facet | Xiaozhe, Li Meilan, Chen Beihui, Huang Junru, Liu Jingli, Gu Lifen, Kuang Juan, Li |
author_sort | Xiaozhe, Li |
collection | PubMed |
description | PURPOSE: Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient’s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM. METHODS: Patients who met the trial’s eligibility requirements were randomized and then administered either pyridoxine 100 mg twice daily or no pyridoxine, in both cases accompanied by their PLD-containing chemotherapeutic agent. Follow-up of patients was performed until the completion of induction therapy, the development of HFS or disease progression. RESULTS: Between January 1, 2017, and January 1, 2019, 105 patients were randomly assigned to the pyridoxine group (n = 52) or the no pyridoxine group (n = 53). In the pyridoxine and no pyridoxine groups, HFS developed after a median of 4 (range, 1-8 cycles) and 3 (range, 1-7 cycles) chemotherapeutic cycles, respectively. There were no grade 3 incidents recorded. Overall, 13.3% of patients experienced HFS. A 11 of 53 (20.8%) patients in the no pyridoxine group experienced HFS, compared to 3 of 52 (5.8%) patients in the pyridoxine group (P = .042); there was no difference in HFS grades (P = .725). CONCLUSIONS: The findings of benefit from prophylactic pyridoxine in this open-label trial have suggested its promise as a treatment for reducing HFS in MM patients. Further research with a placebo-controlled design is recommended. CLINICAL TRIAL REGISTRATION: ChiCTR2100050294. |
format | Online Article Text |
id | pubmed-9751154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-97511542022-12-16 Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study Xiaozhe, Li Meilan, Chen Beihui, Huang Junru, Liu Jingli, Gu Lifen, Kuang Juan, Li Integr Cancer Ther Research Article PURPOSE: Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient’s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM. METHODS: Patients who met the trial’s eligibility requirements were randomized and then administered either pyridoxine 100 mg twice daily or no pyridoxine, in both cases accompanied by their PLD-containing chemotherapeutic agent. Follow-up of patients was performed until the completion of induction therapy, the development of HFS or disease progression. RESULTS: Between January 1, 2017, and January 1, 2019, 105 patients were randomly assigned to the pyridoxine group (n = 52) or the no pyridoxine group (n = 53). In the pyridoxine and no pyridoxine groups, HFS developed after a median of 4 (range, 1-8 cycles) and 3 (range, 1-7 cycles) chemotherapeutic cycles, respectively. There were no grade 3 incidents recorded. Overall, 13.3% of patients experienced HFS. A 11 of 53 (20.8%) patients in the no pyridoxine group experienced HFS, compared to 3 of 52 (5.8%) patients in the pyridoxine group (P = .042); there was no difference in HFS grades (P = .725). CONCLUSIONS: The findings of benefit from prophylactic pyridoxine in this open-label trial have suggested its promise as a treatment for reducing HFS in MM patients. Further research with a placebo-controlled design is recommended. CLINICAL TRIAL REGISTRATION: ChiCTR2100050294. SAGE Publications 2022-12-12 /pmc/articles/PMC9751154/ /pubmed/36510385 http://dx.doi.org/10.1177/15347354221140402 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Article Xiaozhe, Li Meilan, Chen Beihui, Huang Junru, Liu Jingli, Gu Lifen, Kuang Juan, Li Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study |
title | Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study |
title_full | Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study |
title_fullStr | Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study |
title_full_unstemmed | Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study |
title_short | Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study |
title_sort | pyridoxine is effective for preventing hand-foot syndrome induced by pegylated liposomal doxorubicin for multiple myeloma: the results of a randomized study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751154/ https://www.ncbi.nlm.nih.gov/pubmed/36510385 http://dx.doi.org/10.1177/15347354221140402 |
work_keys_str_mv | AT xiaozheli pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy AT meilanchen pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy AT beihuihuang pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy AT junruliu pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy AT jingligu pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy AT lifenkuang pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy AT juanli pyridoxineiseffectiveforpreventinghandfootsyndromeinducedbypegylatedliposomaldoxorubicinformultiplemyelomatheresultsofarandomizedstudy |